natgillin/translations-raw huggingface dataset:
is equal to phenyl-, phenyl-(C1-C4)-alkyl-, wherein the phenyl residues are optionally substituted with 1-3 residues selected independently from F, Cl, Br, CF3, (C1-C6)-alkyl-, (C1-C6)-alkyl-O-, CN, (C1-C2)-alkyl-SO2-, and wherein one or more hydrogen atoms of the alkyl moieties may be replaced by fluorine, with the proviso if in compounds of formula I A is a 3-cyanophenyl residue and X a 2,4-difluorophenyl residue R5 is not 3-methylsulfonyl-phenyl or 4-methylsulfonyl-phenyl; or wherein 
je jednak fenil-, fenil-(C1-C4)-alkil-, gdje su fenilni ostatci proizvoljno supstituirani s 1-3 ostatka koji su odabrani neovisno od F, Cl, Br, CF3, (C1-C6)-alkil-, (C1-C6)-alkil-O-, CN, (C1-C2)-alkil-SO2-, i gdje jedan ili više vodikovih atoma iz alkilnih dijelova mogu biti zamijenjeni s fluorom, uz uvjet da ako u spojevima formule I, A predstavlja 3-cijanofenilni ostatak i X predstavlja 2,4-difluorofenilni ostatak, R5 nije 3-metilsulfonil-fenil ili 4-metilsulfonil-fenil; ili gdje je jednak R7R6N-, gdje
is equal to an aliphatic heterocycle, wherein the aliphatic heterocycle is selected from the group of oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, morpholinyl, piperidinyl, pyrrolidinyl, and wherein the aliphatic heterocycle may be optionally substituted with 1 or 2 substituents selected from the group of F, OH, (C1-C4)-alkyl-O- and (C1-C4)-alkyl-, and wherein one or more hydrogen atoms of the alkyl groups may be replaced by fluorine, with the proviso if in compounds of formula I A is a 3-cyanophenyl residue and X a 2,4-difluorophenyl residue R5 is not 3-methyl-oxetan-3-yl, tetrahydrofuran-3-yl, tetrahydropyran-4-yl or 1-methyl-piperidin-4-yl. 
predstavlja alifatski heterocikal, gdje je alifatski heterocikal odabran iz skupine koju čine oksetanil, tetrahidrofuranil, tetrahidropiranil, morfolinil, piperidinil, pirolidinil, i gdje alifatski heterocikal može biti proizvoljno supstituiran s 1 ili 2 supstituenta odabrana iz skupine koju čine F, OH, (C1-C4)-alkil-O- i (C1-C4)-alkil-, i gdje jedan ili više vodikovih atoma iz alkilnih skupina mogu biti zamijenjeni s fluorom, uz uvjet da ako u spojevima formule I, A predstavlja 3-cijanofenilni ostatak i X predstavlja 2,4-difluorofenilni ostatak, R5 nije 3-metil-oksetan-3-il, tetrahidrofuran-3-il, tetrahidropiran-4-il ili 1-metil-piperidin-4-il.
or wherein R3 and R4 together form an ethylene bridge; 
ili gdje R3 i R4 zajedno tvore etilenski most;
is equal to phenyl-, phenyl-(C1-C2)-alkyl-, wherein the phenyl residues are optionally substituted with 1-3 residues selected independently from F, Cl, Br, CF3, (C1-C2)-alkyl-, (C1-C2)-alkyl-O-, CN, methyl-SO2-, and wherein one or more hydrogen atoms of the alkyl moieties may be replaced by fluorine, with the proviso if in compounds of formula I A is a 3-cyanophenyl residue and X a 2,4-difluorophenyl residue R5 is not 3-methylsulfonyl-phenyl or 4-methylsulfonyl-phenyl; 
ili gdje je jednak fenil-, fenil-(C1-C2)-alkil-, gdje su fenilni ostatci proizvoljno supstituirani s 1-3 ostatka koji su odabrani neovisno od F, Cl, Br, CF3, (C1-C2)-alkil-, (C1-C2)-alkil-O-, CN, metil-SO2-, i gdje jedan ili više vodikovih atoma iz alkilnih dijelova mogu biti zamijenjeni s fluorom, uz uvjet da ako u spojevima formule I, A predstavlja 3-cijanofenilni ostatak i X predstavlja 2,4-difluorofenilni ostatak, R5 nije 3-metilsulfonil-fenil ili 4-metilsulfonil-fenil;
is equal to an aliphatic heterocycle, wherein the aliphatic heterocycle is selected from the group of oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, morpholinyl, piperidinyl, pyrrolidinyl, and wherein the aliphatic heterocycle may be optionally substituted with 1 or 2 substituents selected from the group of F, OH, (C1-C2)-alkyl-O- and (C1-C4)-alkyl-, and wherein one or more hydrogen atoms of the alkyl groups may be replaced by fluorine, with the proviso if in compounds of formula I A is a 3-cyanophenyl residue and X a 2,4-difluorophenyl residue R5 is not 3-methyl-oxetan-3-yl, tetrahydrofuran-3-yl, tetrahydropyran-4-yl or 1-methyl-piperidin-4-yl, and/or of a stereoisomeric form of the compound of the formula I and/or mixtures of these forms, and/or their pharmaceutically acceptable salts. 
predstavlja alifatski heterocikal, gdje je alifatski heterocikal odabran iz skupine koju čine oksetanil, tetrahidrofuranil, tetrahidropiranil, morfolinil, piperidinil, pirolidinil, i gdje alifatski heterocikal može biti proizvoljno supstituiran s 1 ili 2 supstituenta odabrana iz skupine koju čine F, OH, (C1-C2)-alkil-O- i (C1-C4)-alkil-, i gdje jedan ili više vodikovih atoma iz alkilnih skupina mogu biti zamijenjeni s fluorom, uz uvjet da ako u spojevima formule I, A predstavlja 3-cijanofenilni ostatak i X predstavlja 2,4-difluorofenilni ostatak, R5 nije 3-metil-oksetan-3-il, tetrahidrofuran-3-il, tetrahidropiran-4-il ili 1-metil-piperidin-4-il, i/ili stereoizomerni oblik spoja s formulom I, i/ili smjese navedenih oblika, i/ili njihove farmaceutski prihvatljive soli.
is equal to an aliphatic heterocycle, wherein the aliphatic heterocycle is selected from the group of oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, morpholinyl, piperidinyl, pyrrolidinyl, and wherein the aliphatic heterocycle may be optionally substituted with 1 or 2 substituents selected from the group of F, OH, (C1-C4)-alkyl-O- and (C1-C4)-alkyl-, and wherein one or more hydrogen atoms of the alkyl groups may be replaced by fluorine, with the proviso if in compounds of formula I A is a 3-cyanophenyl residue and X a 2,4-difluorophenyl residue R5 is not 3-methyl-oxetan-3-yl, tetrahydrofuran-3-yl, tetrahydropyran-4-yl or 1-methyl-piperidin-4-yl. 
predstavlja alifatski heterocikal, gdje je alifatski heterocikal odabran iz skupine koju čine oksetanil, tetrahidrofuranil, tetrahidropiranil, morfolinil, piperidinil, pirolidinil, i gdje alifatski heterocikal može biti proizvoljno supstituiran s 1 ili 2 supstituenta odabrana iz skupine koju čine F, OH, (C1-C4)-alkil-O- i (C1-C4)-alkil-, i gdje jedan ili više vodikovih atoma iz alkilnih skupina mogu biti zamijenjeni s fluorom, uz uvjet da ako u spojevima formule I, A predstavlja 3-cijanofenilni ostatak i X je 2,4-difluorofenilni ostatak, R5 nije 3-metil-oksetan-3-il, tetrahidrofuran-3-il, tetrahidropiran-4-il ili 1-metil-piperidin-4-il.
is equal to phenyl-, phenyl-(C1-C2)-alkyl-, wherein the phenyl residues are optionally substituted with 1-3 residues selected independently from F, Cl, Br, CF3, (C1-C2)-alkyl-, (C1-C2)-alkyl-O-, CN, methyl-SO2-, and wherein one or more hydrogen atoms of the alkyl moieties may be replaced by fluorine, with the proviso if in compounds of formula I A is a 3-cyanophenyl residue and X a 2,4-difluorophenyl residue R5 is not 3-methylsulfonyl-phenyl, 4-methylsulfonyl-phenyl; 
je jednak fenil-, fenil-(C1-C2)-alkil-, gdje su fenilni ostatci proizvoljno supstituirani s 1-3 ostatka koji su odabrani neovisno od F, Cl, Br, CF3, (C1-C2)-alkil-, (C1-C2)-alkil-O-, CN, metil-SO2-, i gdje jedan ili više vodikovih atoma iz alkilnih dijelova mogu biti zamijenjeni s fluorom, uz uvjet da ako u spojevima formule I, A predstavlja 3-cijanofenilni ostatak i X je 2,4-difluorofenilni ostatak, R5 nije 3-metilsulfonil-fenil, 4-metilsulfonil-fenil;
is equal to an aliphatic heterocycle, wherein the aliphatic heterocycle is selected from the group of oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, morpholinyl, piperidinyl, pyrrolidinyl, and wherein the aliphatic heterocycle may be optionally substituted with 1 or 2 substituents selected from the group of F, OH, (C1-C2)-alkyl-O- and (C1-C4)-alkyl-, and wherein one or more hydrogen atoms of the alkyl groups may be replaced by fluorine, with the proviso if in compounds of formula I A is a 3-cyanophenyl residue and X a 2,4-difluorophenyl residue R5 is not 3-methyl-oxetan-3-yl, tetrahydrofuran-3-yl, tetrahydropyran-4-yl or 1-methyl-piperidin-4-yl, and/or of a stereoisomeric form of the compound of the formula I and/or mixtures of these forms, and/or their pharmaceutically acceptable salts. 
predstavlja alifatski heterocikal, gdje je alifatski heterocikal odabran iz skupine koju čine oksetanil, tetrahidrofuranil, tetrahidropiranil, morfolinil, piperidinil, pirolidinil, i gdje alifatski heterocikal može biti proizvoljno supstituiran s 1 ili 2 supstituenta odabrana iz skupine koju čine F, OH, (C1-C2)-alkil-O- i (C1-C4)-alkil-, i gdje jedan ili više vodikovih atoma iz alkilnih skupina mogu biti zamijenjeni s fluorom, uz uvjet da ako u spojevima formule I, A predstavlja 3-cijanofenilni ostatak i X je 2,4-difluorofenilni ostatak, R5 nije 3-metil-oksetan-3-il, tetrahidrofuran-3-il, tetrahidropiran-4-il ili 1-metil-piperidin-4-il, i/ili stereoizomerni oblik spoja s formulom I, i/ili smjese navedenih oblika, i/ili njihove farmaceutski prihvatljive soli.
A compound of formula I and/or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 15, a medicament according to claim 16 or a compound according to claim 17 for use in the treatment or prevention of arrhythmias, particularly atrial tachyarrhythmias, atrial fibrillation and atrial flutter. 
Spoj s formulom I i/ili njegova farmaceutski prihvatljiva sol prema bilo kojem od zahtjeva 1 do 15, medikament prema zahtjevu 16 ili spoj prema zahtjevu 17 naznačen time da je za uporabu za liječenje ili sprječavanje aritmija, posebno tahiaritmija pretklijetke, fibrilacije atrija i treperenja atrija.
A compound of formula I and/or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 15, a medicament according to claim 16 or a compound according to claim 17 for use in the treatment or prevention of sleep-related respiratory disorders, central and obstructive sleep apneas, upper airway resistance syndrome, Cheyne-Stokes respiration, snoring, disrupted central respiratory drive, sudden child death, postoperative hypoxia and apnea, muscle-related respiratory disorders, respiratory disorders after long-term mechanical ventilation (weaning), respiratory disorders during adaptation in high mountains, acute and for respiratory disorders, chronic lung disorders with hypoxia and hypercapnia, chronic obstructive pulmonary disease (COPD) and obesity hypoventilation syndrome; 
Spoj s formulom I i/ili njegova farmaceutski prihvatljiva sol prema bilo kojem od zahtjeva 1 do 15, medikament prema zahtjevu 16 ili spoj prema zahtjevu 17 naznačen time da je za uporabu za liječenje ili sprječavanje respiratornih poremećaja povezanih sa spavanjem, središnjih i opstrukcijskih apneja za vrijeme spavanja, sindroma povećanog otpora gornjih dišnih putova, Cheyne-Stokesovog disanja, hrkanja, poremećenog središnjeg respiratornog nagona, iznenadne dječje smrti, postoperativne hipoksije i apneje, respiratornih poremećaja povezanih s mišićima, respiratornih poremećaja nakon dugotrajne mehaničke ventilacije (odvikavanje), respiratornih poremećaja kod prilagodbe u visokim planinama, akutnih respiratornih poremećaja, kroničnih plućnih bolesti s hipoksijom i hiperkapnijom, kronične opstruktivne plućne bolesti (KOPB) i sindroma pretilosti–hipoventilacije;
or for use as a respiratory stimulant for the treatment or prevention of respiratory depression associated with anesthesia or procedural sedations for small interventions or for diagnostic purposes, or for use as a respiratory stimulant for the treatment or prevention of respiratory depression by opioids in chronic pain treatment particularly in cancer or palliative care or procedural sedations and/or for weaning from longterm mechanical ventilation; 
ili za uporabu kao respiratorni stimulans za liječenje ili sprječavanje respiratorne depresije vezane uz anesteziju ili proceduralne sedacije za male zahvate ili za dijagnostičke svrhe, ili za uporabu kao respiratorni stimulans za liječenje ili prevenciju respiratorne depresije s opioidima kod liječenja kronične boli, naročito raka ili za palijativnu skrb ili za proceduralnu sedaciju i/ili za odvikavanje od dugotrajne mehaničke ventilacije;
or for use in the treatment or prevention of multiple sclerosis and inflammatory or degenerative disorders of the central nervous system. 
ili za uporabu za liječenje ili prevenciju multiple skleroze i upalnih ili degenerativnih poremećaja središnjeg živčanog sustava.
The method according to any one of claims 1-4, wherein the addition of the WT1 peptide to the antigen-presenting cell is practiced by the addition of the WT1 peptide, the addition of an expression vector comprising the polynucleotide encoding the WT1 peptide or the addition of a cell including the expression vector. 
Postupak prema bilo kojem od zahtjeva 1-4, naznačen time da se dodavanje WT1 peptida u antigen prezentirajuću stanicu prakticira s dodavanjem WT1 peptida, dodavanjem ekspresijskog vektora koji sadrži polinukleotid koji kodira WT1 peptid ili dodavanjem stanice koja sadrži ekspresijski vektor.
A pharmaceutical composition for administration to the stomach of a patient comprising an effective amount of at least one pharmaceutically acceptable zinc salt in combination with a proton pump inhibitor, optionally in combination with a pharmaceutically acceptable carrier, additive or excipient for use to rapidly increase the pH of the gastric juices in the stomach of a patient in need thereof to at least 3.0 within a period no greater than one hour after administration. 
Farmaceutski pripravak za primjenu u želudac bolesnika, koji sadrži učinkovitu količinu barem jedne farmaceutski prikladne cinkove soli u kombinaciji s inhibitorom protonske pumpe, po izboru u kombinaciji s farmaceutski prikladnim nosačem, aditivom ili pomoćnom tvari za uporabu za brzo povećanje pH želučanih sokova u želucu bolesnika kojemu je to potrebno na barem 3.0 u vremenu ne većem od jednog sata nakon primjene.
The composition for use according to claim 1 wherein said amount of zinc salt in said composition is effective to raise the pH of the gastric juices in the stomach of said patient to at least 3.5 within a period no greater than 30 minutes after administration. 
Pripravak za uporabu prema zahtjevu 1 gdje je ta količina cinkove soli u tom pripravku učinkovita da podigne pH želučanih sokova u želucu tog bolesnika na barem 3.5 u vremenu ne većem od 30 minuta nakon primjene.
The composition for use according to claim 1 or 2 wherein said amount of zinc salt is effective to raise the pH of the gastric juices in the stomach of said patient to at least 4.0. 
Pripravak za uporabu prema zahtjevu 1 ili 2 gdje je ta količina cinkove soli učinkovita da podigne pH želučanih sokova u želucu tog bolesnika na barem 4.0.
The composition for use according to any of claims 1-11 wherein said proton pump inhibitor is formulated in sustained release form. 
Pripravak za uporabu prema bilo kojem od zahtjeva 1-11 gdje je taj inhibitor protonske pumpe formuliran u obliku prilagođenog oslobađanja.
The composition for use according to any of claims 1-13 comprising at least two zinc salts, at least one of said zinc salts being formulated in immediate release form and at least one zinc salt being formulated in sustained release form. 
Pripravak za uporabu prema bilo kojem od zahtjeva 1-13 koji sadrži najmanje dvije cinkove soli, barem jedna od tih cinkovih soli je formulirana u obliku koji se odmah oslobađa i barem jedna cinkova sol je formulirana u obliku prilagođenog oslobađanja.
A pharmaceutical composition adapted for administration to the stomach of a patient comprising an effective amount of at least one pharmaceutically acceptable zinc salt in combination with an effective amount of an anti-H. pylori agent, optionally in combination with a pharmaceutically acceptable carrier, additive or excipient for use to rapidly increase the pH of the gastric juices in the stomach of a patient in need thereof to at least 3.0 within a period no greater than one hour after administration. 
Farmaceutski pripravak za primjenu u želudac bolesnika, koji sadrži učinkovitu količinu barem jedne farmaceutski prikladne cinkove soli u kombinaciji s inhibitorom protonske pumpe, po izboru u kombinaciji s farmaceutski prikladnim nosačem, aditivom ili pomoćnom tvari za uporabu za brzo povećanje pH želučanih sokova u želucu bolesnika kojemu je to potrebno na barem 3.0 u vremenu ne većem od jednog sata nakon primjene.
The composition for use according to claim any of claims 1-2 wherein said zinc salt is a mixture of at least two zinc salts. . 
Pripravak za uporabu prema zahtjevu 1 ili 2 gdje je ta količina cinkove soli učinkovita da podigne pH želučanih sokova u želucu tog bolesnika na barem 4.0.
The conjugate for use of claim 11, wherein the method is of treating cancer of the lung, breast, colon, prostate, kidney, pancreas, ovary or lymphatic organs.. 
Konjugat za uporabu prema zahtjevu 24, gdje je postupak liječenje raka pluća, dojke, debelog crijeva, prostate, bubrega, gušterače, jajnika ili limfnih organa.
The compound or salt for use according to claim 1, wherein said compound is selected from: 
Spoj ili sol za upotrebu prema patentnom zahtjevu 1, naznačen time da je naveden spoj izabran od:
The compound or salt for use according to claim 16, wherein said myeloproliferative disorder is polycythemia vera (PV). 
Spoj ili sol za upotrebu prema patentnom zahtjevu 16, naznačen time da je navedeni mijeloproliferativni poremećaj policitemija vera (PV).
The compound or salt for use according to claim 16, wherein said myeloproliferative disorder is essential thrombocythemia (ET). 
Spoj ili sol za upotrebu prema patentnom zahtjevu 16, naznačen time da je navedeni mijeloproliferativni poremećaj esencijalna trombocitemija (ET).
The compound or salt for use according to claim 16, wherein said myeloproliferative disorder is myeloid metaplasia with myelofibrosis (MMM). 
Spoj ili sol za upotrebu prema patentnom zahtjevu 16, naznačen time da je navedeni mijeloproliferativni poremećaj mijeloidna metaplazija sa mijelofibrozom (MMM).
The compound or salt for use according to claim 23, wherein said cancer is breast cancer. 
Spoj ili sol za upotrebu prema patentnom zahtjevu 23, naznačen time da je navedeni tumor tumor dojke.
The compound or salt for use according to claim 37, wherein said DNA-damaging agent is selected from melphalan, doxorubicin, cyclophosphamide, vincristine, etoposide, and carmustine. 
Spoj ili sol za upotrebu prema patentnom zahtjevu 37, naznačen time da je DNK sredstvo oštećenja izabrano od melfalana, doksolrubicina, ciklofosfamida, vinkristina, etopozida, i karmustina.
A system for remodeling a therapeutic zone within tissue underlying a mucosal epithelium of female genital tissue, the apparatus comprising: 
Sustav za remodeliranje terapijske zone unutar tkiva u podlozi epitela sluznice ženskog genitalnog tkiva, pri čemu se aparat sastoji od:
a shaft comprising a longitudinal axis; and an energy delivery element having an epithelium-contacting surface: and an internal cooling chamber configured to internally cool the energy delivery element, wherein the energy delivery element comprises a thermally-conductive surface that is adapted to allow cooling of the epithelium while transmitting RF energy to heat the target tissue; characterised by 
vratila koje se sastoji od uzdužne osovine; i elementa za isporuku energije koji ima površinu u kontaktu s epitelom; i unutarnje rashladne komore konfigurirane za unutarnje hlađenje elementa za isporuku energije, pri čemu se element za isporuku energije sastoji od toplinski provodljive površine koja je prilagođena da omogući hlađenje epitela tijekom prijenosa radiofrekventne (RF) energije radi zagrijavanja ciljnog tkiva;
The apparatus of claim 1, wherein the internal cooling chamber comprises a plurality of coolant nozzles configured to spray cooling fluid on an internal portion of the energy delivery element. 
Aparat prema zahtjevu 1, naznačen time, što unutarnja rashladna komora sadrži više rashladnih mlaznica konfiguriranih da raspršuju rashladnu tekućinu na unutarnji dio elementa za isporuku energije.
The apparatus of claim 1, wherein the energy delivery element comprises at least one RF electrode. 
Aparat prema zahtjevu 1, naznačen time, što element za isporuku energije sadrži najmanje jednu RF elektrodu.
The apparatus of claim 1, further comprising a return coolant pathway extending proximally from the elongate handle configured to channel the used coolant away from a patient. 
Aparat prema zahtjevu 1, koji dalje sadrži povratni put za rashladno sredstvo koji se proteže proksimalno od izdužene ručke konfiguriran da usmjerava rashladno sredstvo dalje od bolesnika.
The apparatus of claim 1, further comprising a flat cable connecting the handle to the controller, the cable including a coolant delivery channel and a coolant return channel, at least one RF power line. 
Aparat prema zahtjevu 1, koji dalje sadrži ravni kabel spojen za ručku kontrolera, pri čemu kabel uključuje kanal za isporuku rashladnog sredstva i povratni kanal za rashladno sredstvo, najmanje jedan RF električni vod.
The apparatus of claim 1, wherein the handle does not include a button or switch controlling the application of RF energy. 
Aparat prema zahtjevu 1, naznačen time, što ručka ne sadrži gumb ili prekidač za kontroliranje primjene RF energije.
The system of claim 1: 
Sustav prema zahtjevu 1:
an RF generator within the housing; and a cooling sub-system within the housing. 
RF generator unutar kućišta; i rashladni podsustav unutar kućišta.
The system of claim 1, wherein the display is configured to display a map of the plurality of energy-delivery elements indicating contact status. 
Sustav prema zahtjevu 1, naznačen time, što je zaslon konfiguriran da prikazuje kartu s više elemenata za isporuku energije koja ukazuje na status kontakta.
The compound of claim 3 wherein A is a bond; 
Spoj u skladu s patentnim zahtjevom 3, naznačen time, da A je veza;
The compound of claim 7 wherein the compound is of formula (Ic), wherein A is a bond; 
Spoj u skladu s patentnim zahtjevom 7, naznačen time, da je spoj formule (Ic), pri čemu A je veza;
The compound of claim 15 wherein R5 is hydrogen, halogen, -NH2 or-N(Ra)(Rb). 
Spoj u skladu s patentnim zahtjevom 15, naznačen time, da R5 je vodik, halogen, -NH2 ili -N(Ra)(Rb).
R4' is selected from hydrogen; 
' je odabran od vodika;
R is selected from 
je odabran od sljedećih
R is selected from halogen- 
R je odabran od sljedećih halogen-
is selected from hydrogen, methyl; 
je odabran od vodika, metila;
R4' is selected from hydrogen, or R4 and R4' together with the nitrogen atom to which they are attached, form morpholinyl, piperidinyl, pyrrolidinyl. 
' je odabran od vodika, ili R4i R4' zajedno s dušikovim atomom na kojega su priključeni, tvore morfolinil, piperidinil, pirolidinil.
A combination in particular a pharmaceutical combination, comprising a therapeutically effective amount of a compound of formula (I) according to any one of claims 1 to 10 and one or more therapeutically active agents, particularly pain-relieving agents. 
Kombinacija, posebno farmaceutska kombinacija, naznačena time, da obuhvaća terapeutski učinkovitu količinu spoja formule (I) prema bilo kojem od zahtjeva 1 do 10, te jedno ili više terapeutski djelotvornih sredstava, posebno sredstava protiv bolova.
A compound of formula (I) according to any one of claims 1 to 10 for use in the treatment of a disorder or disease selected from chronic pain, such as positive symptoms of chronic pain e.g. parethesias, dyesthesias, hyperalgesia, allodynia and spontaneous pain as well as negative symptoms e.g. loss of sensation. 
Spoj formule (I) prema bilo kojem od zahtjeva 1 do 10, naznačen time, da se upotrebljava za liječenje poremećaja ili bolesti odabranih od kroničnih bolova kao što su pozitivni simptomi kroničnih bolova, primjerice paretezije, diestezije, hiperalgezija, alodinija i spontani bolovi; te kao što su i negativni simptomi kroničnih bolova, primjerice gubitak osjetljivosti.